Literature DB >> 26681729

Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.

Stephanie Lankhorst1, Hans J Baelde2, Marian C Clahsen-van Groningen3, Frank M M Smedts4, A H Jan Danser1, Anton H van den Meiracker1.   

Abstract

BACKGROUND: Antiangiogenic treatment with the multitargeted vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib associates with a blood pressure (BP) rise and glomerular renal injury. Recent evidence indicates that VEGF derived from tubular cells is required for maintenance of the peritubular vasculature. In the present study, we focussed on tubular and glomerular pathology induced by sunitinib and explored whether a high salt (HS) diet augments the BP rise and renal abnormalities.
METHODS: Normotensive Wistar Kyoto (WKY) rats were exposed to a normal salt (NS) or HS diet for 2 weeks and subsequently for 8 days to sunitinib or vehicle administration after which the rats were euthanized and kidneys excised. Mean arterial pressure (MAP) was telemetrically measured. Urine was sampled for proteinuria and endothelinuria, and blood for measurement of endothelin-1, creatinine and cystatin C.
RESULTS: Compared with the NS diet, MAP rapidly rose by 27 ± 3 mmHg with the HS diet. On sunitinib, MAP rose further by 15 ± 1 with the NS and by 23 ± 4 mmHg with the HS diet (P < 0.05). The HS diet itself had no effect on proteinuria, endothelinuria or the plasma levels of endothelin-1, creatinine and cystatin C. Only with the HS diet, sunitinib administration massively increased proteinuria and endothelinuria and these two parameters were related (r = 0.50, P < 0.01). Likewise, renal glomerular pathology was enhanced during sunitinib with the HS diet, whereas tubulointerstitial injury or reduced peritubular capillary density did not occur.
CONCLUSIONS: An HS diet induces a marked BP rise in WKY rats and exacerbates both the magnitude of the BP rise and glomerular injury induced by sunitinib.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  angiogenesis inhibition; kidney; salt; sunitinib; vascular endothelial growth factor

Mesh:

Substances:

Year:  2015        PMID: 26681729     DOI: 10.1093/ndt/gfv410

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

Review 1.  Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.

Authors:  Rhian M Touyz; Ninian N Lang; Joerg Herrmann; Anton H van den Meiracker; A H Jan Danser
Journal:  Hypertension       Date:  2017-06-19       Impact factor: 10.190

Review 2.  Management of VEGF-Targeted Therapy-Induced Hypertension.

Authors:  Stefano Caletti; Anna Paini; Maria Antonietta Coschignano; Carolina De Ciuceis; Matteo Nardin; Roberto Zulli; Maria Lorenza Muiesan; Massimo Salvetti; Damiano Rizzoni
Journal:  Curr Hypertens Rep       Date:  2018-06-29       Impact factor: 5.369

Review 3.  VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.

Authors:  Nicholas Camarda; Richard Travers; Vicky K Yang; Cheryl London; Iris Z Jaffe
Journal:  Curr Oncol Rep       Date:  2022-02-18       Impact factor: 5.945

4.  High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease.

Authors:  Meina Zou; Yanrong Chen; Zongji Zheng; Shuyue Sheng; Yijie Jia; Xiangyu Wang; Shijing Ren; Yanling Yang; Xiaomin Li; Wenhui Dong; Meiping Guan; Qian Zhang; Yaoming Xue
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

5.  Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis.

Authors:  Linhan Jiang; Xiaoxia Tan; Jun Li; Yaling Li
Journal:  Front Oncol       Date:  2021-10-12       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.